In Kras-mutant pancreatic ductal adenocarcinoma mice, dual inhibition of MEK and CDK4/6 can induce CS and improve the efficacy of anti-PD-1 therapy67. Here, KRAS is linked to pancreatic ductal adenocarcinoma.